Table 2.
Comparison of quality of life of Brazilian and North American patients with GD receiving enzyme replacement therapy, according to SF-36 survey responses*
| Brazilian patients with Gaucher disease (n = 15) | American patients with Gaucher disease (Masek et al. 2009) (n = 25) | p | |
|---|---|---|---|
| Mean age (years) | 22.3 | 41.7 | |
| Mean treatment time (years) | 8.5 | 2 | |
| SF-36 | |||
| Physical component | |||
| Physical functioning | 76.3 ± 26.0 | 76.7 ± 29.5 | 0.965 |
| Role-physical | 70.0 ± 42.4 | 80.4 ± 32.8 | 0.318 |
| Bodily pain | 76.5 ± 27.3 | 66.3 ± 25.6 | 0.241 |
| General health | 71.1 ± 21.6** | 59.3 ± 24.0** | 0.126 |
| Mental component | |||
| Vitality | 67.6 ± 20.6** | 56.3 ± 23.3** | 0.129 |
| Social functioning | 70.0 ± 20.9** | 87.0 ± 18.6** | 0.011a |
| Role-emotional | 68.8 ± 42.6 | 75.3 ± 36.6 | 0.612 |
| Mental health | 77.3 ± 9.7 | 73.9 ± 14.5 | 0.426 |
*Data described as means and standard deviations for the SF-36 domains.
**Clinically significant changes for the SF-36 scores defined according to the criteria for patients with rheumatoid arthritis in the USA (see Methods)
ap < 0.05